Antibody-Drug Conjugates: Possibilities and Challenges

Overview

Journal Avicenna J Med Biotechnol

Specialty Biomedical Engineering

Date 2019 Feb 26

PMID 30800238

Citations 98

Authors

Mohammad-Reza Nejadmoghaddam

Arash Minai-Tehrani

Ramin Ghahremanzadeh

Morteza Mahmoudi

Rassoul Dinarvand

Amir-Hassan Zarnani

Affiliations

Soon will be listed here.

Abstract

The design of Antibody Drug Conjugates (ADCs) as efficient targeting agents for tumor cell is still in its infancy for clinical applications. This approach incorporates the antibody specificity and cell killing activity of chemically conjugated cytotoxic agents. Antibody in ADC structure acts as a targeting agent and a nanoscale carrier to deliver a therapeutic dose of cytotoxic cargo into desired tumor cells. Early ADCs encountered major obstacles including, low blood residency time, low penetration capacity to tumor microenvironment, low payload potency, immunogenicity, unusual off-target toxicity, drug resistance, and the lack of stable linkage in blood circulation. Although extensive studies have been conducted to overcome these issues, the ADCs based therapies are still far from having high-efficient clinical outcomes. This review outlines the key characteristics of ADCs including tumor marker, antibody, cytotoxic payload, and linkage strategy with a focus on technical improvement and some future trends in the pipeline.

Citing Articles

The validation and clinical bioanalysis of the Bicycle® Toxin Conjugate zelenectide pevedotin in human plasma.

Tweed J, Adams-Dam F, Bader J, Zhang Y, Allanson J, Holmes K Bioanalysis. 2025; 17(3):177-185.

PMID: 39829185 PMC: 11853612. DOI: 10.1080/17576180.2025.2452837.

Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies.

Montagner A, Arleo A, Suzzi F, DAssoro A, Piscaglia F, Gramantieri L Biomolecules. 2025; 14(12.

PMID: 39766289 PMC: 11674819. DOI: 10.3390/biom14121581.

Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review).

Hao W, Rajendran B, Cui T, Sun J, Zhao Y, Palaniyandi T Int J Mol Med. 2024; 55(1).

PMID: 39450552 PMC: 11537269. DOI: 10.3892/ijmm.2024.5447.

Recent advances in targeted drug delivery systems for multiple myeloma.

Pant A, Laliwala A, Holstein S, Mohs A J Control Release. 2024; 376:215-230.

PMID: 39384153 PMC: 11611669. DOI: 10.1016/j.jconrel.2024.10.003.

Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses.

Dong Y, Zhang Z, Luan S, Zheng M, Wang Z, Chen Y J Immunother Cancer. 2024; 12(10).

PMID: 39357981 PMC: 11448212. DOI: 10.1136/jitc-2024-009710.

References

Petrul H, Schatz C, Kopitz C, Adnane L, McCabe T, Trail P . Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2011; 11(2):340-9. DOI: 10.1158/1535-7163.MCT-11-0523. View

Nejadmoghaddam M, Zarnani A, Ghahremanzadeh R, Ghods R, Mahmoudian J, Yousefi M . Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy. Sci Rep. 2017; 7(1):13373. PMC: 5645454. DOI: 10.1038/s41598-017-13682-9. View

Challita-Eid P, Satpayev D, Yang P, An Z, Morrison K, Shostak Y . Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res. 2016; 76(10):3003-13. DOI: 10.1158/0008-5472.CAN-15-1313. View

Sommer A, Kopitz C, Schatz C, Nising C, Mahlert C, Lerchen H . Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors. Cancer Res. 2016; 76(21):6331-6339. DOI: 10.1158/0008-5472.CAN-16-0180. View

Tai Y, Mayes P, Acharya C, Zhong M, Cea M, Cagnetta A . Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014; 123(20):3128-38. PMC: 4023420. DOI: 10.1182/blood-2013-10-535088. View

Strop P, Liu S, Dorywalska M, Delaria K, Dushin R, Tran T . Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 2013; 20(2):161-7. DOI: 10.1016/j.chembiol.2013.01.010. View

Kovtun Y, Audette C, Ye Y, Xie H, Ruberti M, Phinney S . Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006; 66(6):3214-21. DOI: 10.1158/0008-5472.CAN-05-3973. View

Tannir N, Forero-Torres A, Ramchandren R, Pal S, Ansell S, Infante J . Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs. 2014; 32(6):1246-57. DOI: 10.1007/s10637-014-0151-0. View

Beck A, Reichert J . Antibody-drug conjugates: present and future. MAbs. 2014; 6(1):15-7. PMC: 7098595. DOI: 10.4161/mabs.27436. View

10.

Sharkey R, Govindan S, Cardillo T, Goldenberg D . Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther. 2011; 11(1):224-34. DOI: 10.1158/1535-7163.MCT-11-0632. View

11.

Sengupta S, Kulkarni A . Design principles for clinical efficacy of cancer nanomedicine: a look into the basics. ACS Nano. 2013; 7(4):2878-82. PMC: 3876731. DOI: 10.1021/nn4015399. View

12.

Younes A, Kim S, Romaguera J, Copeland A, Farial S, Kwak L . Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol. 2012; 30(22):2776-82. PMC: 5950497. DOI: 10.1200/JCO.2011.39.4403. View

13.

Heist R, Guarino M, Masters G, Purcell W, Starodub A, Horn L . Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017; 35(24):2790-2797. DOI: 10.1200/JCO.2016.72.1894. View

14.

Lammerts van Bueren J, Bleeker W, Bogh H, Houtkamp M, Schuurman J, van de Winkel J . Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res. 2006; 66(15):7630-8. DOI: 10.1158/0008-5472.CAN-05-4010. View

15.

WILLNER D, Trail P, Hofstead S, KING H, Lasch S, Braslawsky G . (6-Maleimidocaproyl)hydrazone of doxorubicin--a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug Chem. 1993; 4(6):521-7. DOI: 10.1021/bc00024a015. View

16.

Cardarelli P, Rao-Naik C, Chen S, Huang H, Pham A, Moldovan-Loomis M . A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother. 2009; 59(2):257-65. PMC: 11030752. DOI: 10.1007/s00262-009-0746-z. View

17.

Firth D, Bell L, Squires M, Estdale S, McKee C . A rapid approach for characterization of thiol-conjugated antibody-drug conjugates and calculation of drug-antibody ratio by liquid chromatography mass spectrometry. Anal Biochem. 2015; 485:34-42. DOI: 10.1016/j.ab.2015.06.001. View

18.

Moore K, Martin L, OMalley D, Matulonis U, Konner J, Perez R . Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2016; 35(10):1112-1118. PMC: 5559878. DOI: 10.1200/JCO.2016.69.9538. View

19.

Chari R . Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2007; 41(1):98-107. DOI: 10.1021/ar700108g. View

20.

Azvolinsky A . Conjugating antibodies to cytotoxic agents: getting the best of both worlds?. J Natl Cancer Inst. 2013; 105(23):1765-6. DOI: 10.1093/jnci/djt354. View